@article{3049526,
    title = "Soluble interleukin-2 receptor is a thyroid hormone-dependent
early-response marker in the treatment of thyrotoxicosis",
    author = "Smallridge, RC and Tsokos, GC and Burman, KD and Porter, L and Cranston, and T and Sfikakis, PP and Solomon, BL",
    journal = "Clinical and Diagnostic Laboratory Immunology",
    year = "1997",
    volume = "4",
    number = "5",
    pages = "583-586",
    publisher = "AMER SOC MICROBIOLOGY",
    doi = "10.1128/CDLI.4.5.583-586.1997",
    abstract = "Thyrotoxic patients exhibit increased levels of immune activation
molecules (soluble interleukin-2 receptor [sIL-2R], intercellular
adhesion molecule-1 [ICAM-1], and endothelial-leukocyte adhesion
molecule-1 [ELAM-1]) in serum, although the clinical significance of
these measurements remains unclear, In a randomized ii-week study, we
have recently shown that in the treatment of hyperthyroidism, the
combination of cholestyramine and methimazole (MMI) resulted in faster
lowering of serum thyroid-hormone levels than did MMI alone, Stored
serial serum samples from patients participating in this randomized
treatment trial were analyzed for sIL-2R, soluble ICAM-1 (sICAM-1), and
soluble ELAM-1 (sELAM-1), The levels of all three molecules were
elevated in patients with hyperthyroidism, Although the levels of
sICAM-1 and sELAM-1 remained elevated through the 4-week follow-up
period in both groups of patients, the sIL-2R levels (normal levels, 1.0
to 4.2 ng/ml) decreased significantly in the 10 patients who received
cholestyramine in addition to MMI (week 0, 14.2 +/- 1.5 ng/ml; week 2,
10.8 +/- 1.2 ng/ml; week 4, 8.9 +/- 1.5 ng/ml). In eight patients who
received MMI alone, sIL-2R decreased less rapidly (week 0, 12.3 +/- 1.4
ng/ml; week 2, 12.3 +/- 1.3 ng/ml; week 4, 10.9 +/- 1.3 ng/ml), sICAM-1
and sELAM-1 were elevated at baseline but did not decrease during
therapy, In the former group, free thyroxine and free triiodothyronine
decreased faster, These data show that levels of sIL-2R in serum, but
not those of sICAM-1 and sELAM-1, mag be of clinical use in the early
follow-up evaluation of medically treated patients."
}